Tami Pilot-Matias.

Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D.: Stage 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 Chronic hepatitis C virus infection is a leading cause of cirrhosis, liver cancer, and end-stage liver disease.1 The current standard of care for chronic HCV genotype 1 infection is pegylated interferon and ribavirin, with a protease inhibitor .2 Although the addition of a protease inhibitor has been connected with a significant increase in response prices, only approximately 1 / 3 of patients who had not had a response to prior therapy with peginterferon and ribavirin had a sustained virologic response when re-treated with the addition of a protease inhibitor.3,4 Furthermore, these therapies are associated with adverse effects that can result in early discontinuation of treatment.5-7 Patient characteristics, such as host genetic factors , HCV subtype 1a, black competition, and high baseline viral load, are also associated with poor response rates.6-8 New interferon-free of charge therapies with higher activity in difficult-to-treat sufferers with HCV infection are needed.In addition, AMAG received the $60 million upfront payment from Takeda in April 2010, which is definitely therefore not included in the Company’s money balance by March 31, 2010. Revenues for the one fourth ended March 31, 2010 were $13.3 million when compared with revenues of $1.0 million for the same period in 2009 2009. The upsurge in revenues in 2010 2010 over the similar 2009 period was attributable to Feraheme product product sales following its FDA acceptance and subsequent start in July 2009. Total operating expenses and charges for the one fourth ended March 31, 2010 were $36.8 million as compared to $28.9 million for the same period in 2009 2009.